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Abstract The success of modern, evidence based and personalized medical
research is highly dependent on the availability of a sufficient data basis in terms of
quantity and quality. This often also implies topics like exchange and consolida-
tion of data. In the area of conflict between data privacy, institutional structures
and research interests, several technical, organizational and legal challenges
emerge. Coping with these challenges is one of the main tasks of information
management in medical research. Using the example of cancer research, this case
study points out the marginal conditions, requirements and peculiarities of han-
dling research data in the context of medical research.
Introduction
First the general importance of data exchange and consolidation will be discussed.
In the second section, the important role of the patient in medical research will be
addressed and how it affects the handling of data. The third section focuses on the
question what the role of open data could be in this context. Finally, the fourth
section tackles the topic of challenges of open data in the context of medical
(research) data. It tries to illustrate why it is a problem and what the obstacles are.
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Importance of Data Exchange and Consolidation
With oncology striving after personalized medicine and individualized therapy,
stratification becomes a major topic in cancer research. The stratification of tumor
biology and patients is important to provide individual therapies with maximum
tumor control (optimally total remission) and minimal side effects and risks for the
patient. Therefore, the search for diagnostic markers, e.g. diagnostic imaging,
antibody tests or genome analysis, as well as for adequate treatments with respect
to specific markers is constantly intensified.
Looking at research results, it becomes obvious that cancer diseases (e.g.
prostate cancer or breast cancer) are more like disease families with a multitude of
sub-types and that the anatomical classification of tumors might be misleading and
a classification according to the pathological change of signaling pathways on the
cellular level is more adequate. This differentiation is very relevant because for
one patient a certain treatment may be effective and absolutely relevant while it
has no positive impact on tumor control for other patients with the ‘‘same’’ cancer
and only bears side effects.
In order to have an evidence-based medicine with a sound statistical basis, the
amount and quality of available data becomes very important. The required
amount of data increases with the number of relevant factors. Looking at the
current cancer research, one has a vast array of factors and information—and it is
still increasing. One has for example the patient and tumor biology (e.g. a mul-
titude of diagnostic images; analysis of the genome, proteome etc.; lab results; cell
pathologies; …); way of living before and after the diagnose/therapy; environ-
mental factors and chosen individual therapy.
The current situation can therefore be characterized as too few cases for too
many factors. The size of sample sets even large institutions can collect is too
small for evidence-based and highly stratified medicine. John Wilbanks, the chief
commons officer of Sage Bionetworks,1 put this fact more bluntly:
[…] neither Google nor Facebook would make a change to an advertising algorithm with a
sample set as small as that used in a Phase III clinical trial.
John Wilbanks, Sage Bionetworks
Kotz, J.; SciBX 5(25); 2012
One strategy to tackle these shortcomings is to build up networks and initiatives
and pool the data to acquire sufficient sample sets2. This is not a trivial task
because of the heterogeneity of the public health sector that has to be managed.
1 Sage Bionetworks is the name of a research institute which promotes biotechnology by
practicing and encouraging Open Science. It is founded with a donation of the pharmaceutical
services company Quinitles. cf. http://en.wikipedia.org/wiki/Sage_Bionetworks.
2 An Example is the German Consortium for Translational Cancer Research (Deutsches
Konsortium für Translationale Krebsforschung, DKTK; http://www.dkfz.de/de/dktk/index.html).
One objective in the DKTK is the establishement of a clinical communication platform. This
platform aims amongst others to better coordinate and standardize multi centric studies.
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You have got several stakeholders, heterogeneous documentation of information
(different in style, recorded data, formats, storage media) and different operational
procedures (time and context of data acquisition).
Thus, it is inevitable to cope with this heterogeneity and to build large study
bases by sharing and pooling medical research data in order to realize evidence-
based personalized medicine. One way to achieve this goal could be the adaption
of ideas and concepts of open research data (see below).
Role of the Patient and its Data
As described in the previous section, data is of high importance. This data cannot
be collected without patients and their cooperation is crucial on several levels. This
leads to a very central role for the patient and, in addition, to a special nature of
medical data and its acquisition compared to other research data.
1. Medical data is personal data
By default medical data is always personal data. The implications that derive
from this fact may vary according to the legal framework of a country (e.g. USA:
Health Insurance Portability and Accountability Act (HIPAA); Germany: right to
informational self-determination/personal rights), but it has almost always an
impact on how medical data may be acquired, stored and used. In Germany, for
instance, an individual (in this context a patient) must always be able to query
which personal information is stored, where the information is stored and for
which purpose this information is used. The information may only be altered,
transferred, used, stored or deleted with according permission and sufficient
traceability guaranteed.
2. Ethics
Having an experimental setup that allows the acquisition of data suitable for
verifying or falsifying the scientific hypothesis goes without saying. But in the
context of human research it is also mandatory to ensure that ethical principles are
regarded. These principles are often derived from the Declaration of Helsinki3 and
implemented by national regulations (e.g. USA: institutional review boards;
Germany: Ethikkommision). Thus every study design is reviewed and needs ethic
approval. This may lead to situations where experimental setups are optimal from
a technocratic research perspective but cannot be approved ethically and therefore
must be altered or not conducted.
3 The Declaration was originally adopted in June 1964 in Helsinki, Finland. The Declaration is
an important document in the history of research ethics as the first significant effort of the medical
community to regulate research itself, and forms the basis of most subsequent documents.
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3. Lack of predictability and limits of measurements
Most research-relevant incidents (e.g. (re)occurrence of an illness, adverse
reactions) are not predictable and not projectable (fortunately; see ‘‘Ethics’’).
Therefore, you have to wait until enough natural incidents have happened and are
monitored. The latter can be complicated, because not every measurement tech-
nique can be used arbitrarily frequent due to technical, ethical4 or compliance5
reasons. Without the possibilities to repeat6 ‘‘measurements’’ and in conjunction
with the heterogeneity explained in the previous section, getting a sufficient
number of cases is a nontrivial task.
4. Long ‘‘field’’ observation periods
In order to derive conclusions that really matter for patients, like ‘‘improved
survival’’or ‘‘improved quality of life’’ you need observation periods of 10 and
more years. In this time, the individuals will move around in the distributed public
health system (e.g. by changing their place of residence, choosing new general
practitioners). Data will be accumulated, but is not centrally available because of
the heterogeneous nature of the system. Therefore, keeping track on a study
participant and assembling a non-biased, non-filtered view on study relevant data7
can be very complicated.
5. Compliance
Besides all the explained technical and organizational problems, the key
stakeholder is the study participant/patient and its compliance to the study and the
therapy. If the participant is not compliant to the study, he drops out, which results
in missing data. This missing data can lead to a selection bias and must be handled
with expertise in order to make a reliable assessment of the trial’s result. The
dropout rates vary and depend on the study; rates around 20 % are not unusual,
also rates up to 50 % have been reported.
Participants that are not therapy compliant alter the therapy or skip it totally
(e.g. changing medication; skipping exercises; taking additional drugs). According
to a report (WHO 2003) of the World Health Organization up to 50 % of the
patients are not therapy compliant. An unnoticed lack of therapy compliance may
introduce a bias towards the trial results.
4 e.g.: you cannot repeat an x-ray based imaging arbitrarily often, due to radiation exposition;
you cannot expect a person suffering from cancer to daily lie in an MRI scanner for an hour.
5 e.g.: The payload for an imaging study can easily double the duration of an examination. This
may lead to more stress for the participant and decreasing compliance.
6 Single measurements can be repeated (but this implies stress and leads to decreasing
compliance; or is not ethically not compliant). But the complete course of treatment cannot be
repeated; if a treatment event is missed, it is missed.
7 This could be a lot of (different) data. See for example the relevant factors from
section Importance of Data Exchange and Consolidation.
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6. Consent
The patient has to consent8 on three levels before he can be part of a medical
trial. First, he must consent to a therapy that is relevant for the trial. Second, if all
inclusion criteria and no exclusion criteria for the trial are met, the patient must
consent to be part of the trial. Third, the patient must consent to the usage of the
data. The third consent exists in different types, namely: specific, extended,
unspecific/broad. The specific consent limits the usage to the very trial it was made
for. In the context of open data this type of consent is not useful and is considered
as limiting by many researchers (see challenges). The extended consent often
allows the usage for other questions in the same field as the original trial (e.g.
usage for cancer research). If it is extended to a level where any research is
allowed, it is an unspecific consent. An example for this type of consent is the
Portable Legal Consent devised by the project ‘‘Consent to Research’’.9
You may find each aspect in other types of research data, but the combination
of all six aspects is very distinctive for medical research data and makes special
handling necessary.
Role of Open Research Data
The chapter ‘‘Open Research Data: From Vision to Practice’’ in this book gives an
overview over the benefits open data is supposed to bring. Websites like ‘‘Open
Access success stories’’10 try to document these benefits arising from Open
Access/Open Science. Also in the broad field of medical research, many groups
advocate a different handling of data (often in terms of open data).
One main reason is the requirement of transparency and validation of results
and methods. For example in the domain of medical image processing the research
data (test data, references and clinical meta data) is often not published. This
renders the independent testing and verification of published results, as well as the
translation into practice very difficult. Thus initiatives like the concept of Deserno
8 The necessity for an informed consent of the patient can be derived from legal (see point 1) and
ethical (see point 2) requirements. It is explained in detail here to characterize the different types
of consent.
9 ‘‘Consent to Research’’/WeConsent.us, is an initiative by John Wilbanks/Sage Bionetwirks
with the goal to create an open, massive, mine-able database of data about health and genomics.
One step is the Portable Legal Consent as a broad consent for the usage of data in research.
Another step is the We the People petition lead by Wilbanks and signed by 65,000 people.
February 2013 the US Government replied and announced a plan to open up taxpayer-funded
research data and make it available for free.
10 http://www.oastories.org: The site is provided by the initiative knowledge-exchange.info
which is supported by Denmark’s Electronic Research Library (DEFF, Denmark), the German
Research Foundation (DFG, Germany), the Joint Information Systems Committee (JISC; UK)
und SURF (Netherlands).
Challenges of Open Data in Medical Research 301
et al. (2012) try to build up open data repositories. Another example would be the
article of Begley and Ellis (2012), which discusses current problems in preclinical
cancer research. Amongst others, it recommends a publishing of positive and
negative result data in order to achieve more transparency and reliability of
research.
Besides this, several groups (e.g. the Genetic Alliance11 or the former men-
tioned project Consent to Research) see Open Access to data as the only sensible
alternative to the ongoing privatization of Science data and results. For instance
the company 23 and Me offers genome sequencing for $99.12 In addition to
the offered service the company builds up a private database for research and the
customers consent that this data may be used by the company to develop intel-
lectual property and commercialize products.13
Another topic where the research community could benefit from the imple-
mentation of open data publishing is the heterogeneity of data (see next section:
challenges). Making data available means, that it is:
• open (in terms of at least one public proceeding to get access)
• normed (content of data and semantics are well defined)
• machine readable
• in standardized format.
Having this quality of data would be beneficial, for instance, for radiology,
whose ‘‘[…] images contain a wealth of information, such as anatomy and
pathology, which is often not explicit and computationally accessible […]’’, as
stated by Rubin et al. (2008). Thus, implementing open data could be an oppor-
tunity to tackle this problem as well.
Challenges
The previous sections have discussed the need for data consolidation, the pecu-
liarities of medical research data and how medical research is or could be (posi-
tively) affected by concepts of open research data. It is irrelevant which approach
is taken in order to exchange and consolidate data, you will always face challenges
and barriers on different levels: regulatory, organizational and technical.
The general issues and barriers are discussed in detail by Pampel and Dall-
meier-Tiessen (see chapter Open Research Data: From Vision to Practice). This




13 The article of Hayden (2012a) discusses the topic of commercial usage on the occasion of the
first patent (a patented gen sequence) of the company 23 and me.
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Regulatory constraints for medical (research) data derive from the necessity of
ethic approval and legal compliance when handling personal data (see sec-
tion Role of the Patient and Its Data, point 1 and 2). There are still open discus-
sions and work for the legislative bodies to provide an adequate frame. The article
of Hayden (2012a) depicts the informed consent as a broken contract and illus-
trates how today on one hand participants feel confused by the need of ‘‘reading
between the lines’’, on the other hand researchers cannot pool data due to specific
consents and regulatory issues.
Although there are open issues on the regulatory level, ultimately it will be the
obstacles on the organizational and technical level—which may derive from
regulatory decisions—which determine if and how open data may improve med-
ical research. Therefore, two of these issues will be discussed in more detail.
Pooling the Data
Given that the requirements are met and you are allowed to pool the data of
different sources for your medical research, you have to deal with two obstacles:
mapping the patient and data heterogeneity.
As previously noted, patients move within the public health system and
therefore medical records are created in various locations. In order to pool the data
correctly, you must ensure that all records originated with an individual are
mapped towards it but no other records. Errors in this pooling process lead either
to ‘‘patients’’ consisting of data from several individuals or the splitting of one
individual in several ‘‘patients’’. Preventing these errors from happening can be
hard to implement because prevention strategies are somehow competing (e.g. if
you have very strict mapping criteria, you minimize the occurrence of multi-
individual-patients but have a higher change of split individuals due to typing
errors in the patient name).
In the case that you have successfully pooled the data and handled the mapping
of patients, the issue of heterogeneity remains. This difference of data coverage,
structure and semantics between institutions (which data they store, how the data is
stored and interpreted) makes it difficult to guarantee comparability of pooled data
and to avoid any kind of selection bias (e.g.: Is an event really absent or just not
classified appropriately by a pooled study protocol).
Anonymization, Pseudonymization and Reidentification
Individuals must be protected from (re)identification via their personal data used for
research. German privacy laws, for instance, define anonymization and pseudon-
ymization as sufficient, if they prohibit reidentification or reidentification is only
possible with a disproportional large expenditure of time, money and workforce.14
14 see § 3 (6) Federal Data Protection Act or corresponding federal state law.
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Ensuring this requirement becomes increasingly harder due to technical progress,
growing computational power and—ironically—more open data.
Reidentification can be done via data-mining of accessible data and so-called
quasi-identifiers, a set of (common) properties that are—in their combination—so
specific that they can be used to identify. A modern everyday life example would
be Panopticlick.15 It is a website of the Electronic Frontier Foundation that
demonstrates the uniqueness of a browser (Eckersley 2010) which serves as a
quasi-identifier. Therefore, a set of ‘‘harmless’’ properties is used, like screen
resolution, time zone or installed system fonts.
The following examples illustrate possibilities and incidents of reidentification:
a. Simple demographics: The publications of Sweeney (2000) and Golle (2006)
indicate that for 63–87 % of the U.S. citizens the set of birth date, sex and
postal code is unique and a quasi-identifier.
b. ICD codes: Loukides et al. (2010) assume that 96.5 % of the patients can be
identified by their set of ICD916 diagnoses codes. For their research the Van-
derbilt Native Electrical Conduction (VNEC) dataset was used. The data set
was compiled and published for an NIH17 funded genome-wide association
study.
c. AOL search data: AOL put anonymized Internet search data (including health-
related searches) on its web site. New York Times reporters (Barbaro et al.
2006) were able to re-identify an individual from her search records within a
few days.
d. Chicago homicide database: Students (Ochoa et al. 2001) were able to
re-identify a 35 % of individuals in the Chicago homicide database by linking it
with the social security death index.
e. Netflix movie recommendations18: Individuals in an anonymized publicly
available database of customer movie recommendations from Netflix are
re-identified by linking their ratings with ratings in a publicly available Internet
movie rating web site.
f. Re-identification of the medical record of the governor of Massachusetts: Data
from the Group Insurance Commission, which purchases health insurance for
state employees, was matched against the voter list for Cambridge, re-identi-
fying the governor’s health insurance records (Sweeney 2002).
15 see https://panopticlick.eff.org/
16 ICD: International Classification of Diseases. It is a health care classification system that
provides codes to classify diseases as well as a symptoms, abnormal findings, social
circumstances and external causes for injury or disease. It is published by the World Health
Organization and is used worldwide; amongst others for morbidity statistics and reimbursement
systems.
17 National Institutes of Health; USA.
18 See http://www.wired.com/threatlevel/2009/12/netflix-privacy-lawsuit and http://www.
wired.com/science/discoveries/news/2007/03/72963.
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The examples illustrate the increasing risk of reidentification and the boundary
is constantly pushed further. If you look for example at the development of
miniaturised DNA sequenzing systems19 (planned costs of US$1,000 per device),
sequencing DNA (and using it as data) will presumably not stay limited to insti-
tutions and organisations who can afford currently expensive sequencing
technologies.
Thus proceedings that are compliant to current privacy laws and the common
understanding of privacy are only feasible if data is dropped or generalized (e.g.
age bands instead of birth date or only the first two digits of postal codes). This
could be done for example by not granting direct access to the research data but
offering a view tailored for the specific research aims. Each view ponders the
necessity and usefulness of each data element (or possible generalizations) against
the risk of reidentification.
Even if an infrastructure is provided that enables the filtering of data described
above, you will always have medical data that is easily reidentifiable and at least
hard to be pseudonymized. Good examples are radiological head or whole body
Fig. 1 Example for a magnetic resonance head image (MRI). The upper MRI shows an original
layer of data set of an study participant (axial view, parallel to the feet). The MRIs below are
reconstructions of the original data in sagittal view (left) and coronal view (right). The sagittal
view is similar to a head silhouette and therefore more familiar
19 e.g. the MinIONTM device from Oxford Nanopore Technologies (http://www.
nanoporetech.com). See also (Hayden 2012b).
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images. Figure 1 shows head images from a study participant.20 The original
perspective of the image (axial view) and the other medical perspectives (sagittal
and coronal view) may not be suitable for reidentification by everyman. But a
simple volume rendering of the data (Fig. 2) allows easy reidentification. Starting
from this point with modern technologies several scenarios are not too far-fetched.
An artificial picture, for instance, could be reconstructed and used with available
face recognition APIs21 or you could take the volume data convert it into a 3D
model and print it via a 3D-printer.22
Open Access This chapter is distributed under the terms of the Creative Commons Attribution
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are credited.
20 The data shown in Figs. 1 and 2 are provided by courtesy of Markus Graf (German Cancer
Research Center).
21 One example would be web API offered by face.com (http://en.wikipedia.org/wiki/Face.com).
22 In order to print 3D-Models you can use services like www.shapeways.com or http://
i.materialise.com.
Fig. 2 Volumetric rendering
of the data set shown in
Fig. 1. The possibility to
reidentify is now strikingly
obvious. Volumetric
rendering can easily be done
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